type of report	**Current report**
number	61/2012
company	PHARMENA

Realisation of the Company's Strategy for 2012-2015 in the area dietary supplement 1-MNA

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012), the Management Board of PHARMENA S.A. informs that a consultancy agency has completed an analysis of documentation gathered by the Company and selected the optimal path to the procedural conduct of the registration process of dietary supplement based on the 1-MNA as new foodstuff within the European procedure.

The analysis of the collected documentation indicated that the Company possesses all documents required for applying for authorisation of 1-MNA as new foodstuff, except from in vitro genotoxicological test. Thus, the Company commissioned the lacking study to be carried out. Its completion is planned for November/December 2012. Currently, an application for authorisation of 1-MNA within the European procedure is being prepared. After receiving the report from this study, the Company will promptly submit its application in an EU member state of its choice. Positive registration will open EU markets for the product. The Company intends to register the dietary supplement in 2013.

The 1-MNA dietary supplement is an innovative product that has a capacity to influence the risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin which reduces the risk of atherosclerosis development.

Placing on the market of the innovative dietary supplement (new foodstuff) based on 1-MNA, which is used to meet special nutritional needs in the prevention of atherosclerosis, will become a new area of the Company's operations. It is estimated that only in Poland there are 18 million people threatened with atherosclerosis, of which only 8 million is aware of that fact. Atherosclerosis is one of the most significant civilisation diseases, and together with cancer, it is one of the most common causes of death in the world. The market of OTC products in Poland in the category "Heart and vascular system" was estimated at 271 million PLN in 2011 (according to IMS). Within 3 years from the introduction of the product, the Company intends to reach market share of 6%, and eventually of 12%. Moreover, having registered the 1-MNA dietary supplement within the European procedure, the Company intends to receive revenue from sale (or licence for sale) of the product on EU markets.

The European procedure is an application procedure compliant with the provisions of Art. 4 of Regulation (EC) no. 258/97 of the European Parliament and of the Council of 27th January 1997, which proves the safety and purposefulness of the use of novel food ingredient. Within this procedure, the entity responsible for placing on the Community market submits appropriate application to EU member state, where the new foodstuff is to be first placed on the market. An additional scientific assessment is performed at European level by European Food Safety Authority. Following the assessment, the European Commission, by relevant supervision authorities, grants permission for placing the new foodstuff on the market.

The information is made public due to the fact that placing the innovative 1-MNA dietary supplement on the market, may have significant influence on the Company's revenue in the next few years.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board